Acquired Resistance to KRASG12C Inhibition in Cancer.

doi:10.1056/NEJMoa2105281

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Acquired Resistance to KRASG12C Inhibition in Cancer.

The New England journal of medicine - 24 Jun 2021

Awad Mark M, Liu Shengwu, Rybkin Igor I, Arbour Kathryn C, Dilly Julien, Zhu Viola W, Johnson Melissa L, Heist Rebecca S, Patil Tejas, Riely Gregory J, Jacobson Joseph O, Yang Xiaoping, Persky Nicole S, Root David E, Lowder Kristen E, Feng Hanrong, Zhang Shannon S, Haigis Kevin M, Hung Yin P, Sholl Lynette M, Wolpin Brian M, Wiese Julie, Christiansen Jason, Lee Jessica, Schrock Alexa B, Lim Lee P, Garg Kavita, Li Mark, Engstrom Lars D, Waters Laura, Lawson J David, Olson Peter, Lito Piro, Ou Sai-Hong I, Christensen James G, Jänne Pasi A, Aguirre Andrew J

Abstract excerpt

BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRASG12C). The mechanisms of acquired resistance to these therapies are currently unknown. METHODS: Among patients with KRASG12C -mutant cancers treated with adagrasib monotherapy, we performed genomic and histologic analyses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Piperazines

Share to Protein Conformation

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 34161704
DOI: 10.1056/NEJMoa2105281
PMCID: PMC8864540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Resistance to KRASG12C Inhibition in Cancer.PMID 34161704Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancerSemantic proximity Read ↗

Diverse alterations associated with resistance to KRAS(G12C) inhibition.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.Semantic proximity Read ↗

Differential Response and Resistance to KRAS-Targeted Therapy.Semantic proximity Read ↗

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.Semantic proximity Read ↗

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Assessment of KRASG12C inhibitors for colorectal cancerSemantic proximity Read ↗

Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.